Part of his project on Confidence interval includes research on Hazard ratio and Quartile. In his works, Kristian Wachtell performs multidisciplinary study on Hazard ratio and Confidence interval. His research on Cardiology often connects related areas such as Muscle hypertrophy. Muscle hypertrophy connects with themes related to Cardiology in his study. In his articles, Kristian Wachtell combines various disciplines, including Blood pressure and Brachial artery. He connects Left ventricular hypertrophy with Electrocardiography in his research. Kristian Wachtell integrates many fields, such as Electrocardiography and Left ventricular hypertrophy, in his works. His Internal medicine study often links to related topics such as Diastole. He performs integrative study on Diastole and Blood pressure in his works.
His study connects Microalbuminuria and Internal medicine. His Cardiology study frequently intersects with other fields, such as Vascular resistance. He integrates Blood pressure and Body mass index in his studies. In his articles, Kristian Wachtell combines various disciplines, including Body mass index and Blood pressure. In his papers, he integrates diverse fields, such as Left ventricular hypertrophy and Myocardial infarction. Kristian Wachtell performs integrative study on Myocardial infarction and Left ventricular hypertrophy. His Endocrinology study frequently draws connections between adjacent fields such as Muscle hypertrophy. His Muscle hypertrophy study frequently links to related topics such as Cardiology. His Angiotensin II study frequently draws connections to other fields, such as Losartan.
Kristian Wachtell regularly links together related areas like Confidence interval in his Internal medicine studies. As part of his studies on Confidence interval, Kristian Wachtell often connects relevant subjects like Internal medicine. His multidisciplinary approach integrates Blood pressure and Left ventricular hypertrophy in his work. Kristian Wachtell combines Left ventricular hypertrophy and Blood pressure in his studies. His Cardiology study often links to related topics such as Muscle hypertrophy. His Muscle hypertrophy study frequently links to other fields, such as Cardiology. Kristian Wachtell integrates Heart failure and Ejection fraction in his studies. His work often combines Ejection fraction and Heart failure studies. His study in Clinical endpoint extends to Alternative medicine with its themes.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
Anne B. Rossebø;Terje R. Pedersen;Kurt Boman;Philippe Brudi.
The New England Journal of Medicine (2008)
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End point reduction in hypertension (LIFE) study
Kristian Wachtell;Mika Lehto;Eva Gerdts;Michael H. Olsen.
Journal of the American College of Cardiology (2005)
Prognostic significance of left ventricular mass change during treatment of hypertension
Richard B Devereux;Kristian Wachtell;Eva Gerdts;Krister K. Boman.
JAMA (2004)
Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study
Kristian Wachtell;Hans Ibsen;Michael H. Olsen;Knut Borch-Johnsen.
Annals of Internal Medicine (2003)
Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients. Losartan Intervention for Endpoint Reduction in Hypertension Study
Hans Ibsen;Michael H. Olsen;Kristian Wachtell;Knut Borch-Johnsen.
Hypertension (2005)
Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial
Richard B. Devereux;Björn Dahlöf;Eva Gerdts;Kurt Boman.
Circulation (2004)
A Call to Action and a Lifecourse Strategy to Address the Global Burden of Raised Blood Pressure on Current and Future Generations: The Lancet Commission on Hypertension
Michael H. Olsen;Michael H. Olsen;Sonia Y. Angell;Samira Asma;Pierre Boutouyrie.
The Lancet (2016)
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Lars H. Lindholm;Hans Ibsen;Knut Borch-Johnsen;Michael Hecht Olsen.
Journal of Hypertension (2002)
Prevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition: A Meta-Analysis
Markus P. Schneider;Tsushung A. Hua;Michael Böhm;Kristian Wachtell.
Journal of the American College of Cardiology (2010)
Risk prediction is improved by adding markers of subclinical organ damage to SCORE.
Thomas Sehestedt;Jørgen Jeppesen;Tine W. Hansen;Kristian Wachtell.
European Heart Journal (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Cornell University
Sahlgrenska University Hospital
University of Helsinki
University of Oslo
Cornell University
University of Michigan–Ann Arbor
Copenhagen University Hospital
University of Naples Federico II
Oslo University Hospital
National Institutes of Health